KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Post Hoc, Sex-Specific Subgroup Analysis of Efgartigimod in Patients With Generalized Myasthenia Gravis From the ADAPT Trial: A Sex and Gender Equity in Research (SAGER) Guidelines Approach.

Sarah Hoffmann, Sihui Zhao, Filip Callewaert, Silke Schoppe, Csilla Rózsa, Jennifer Spillane

Muscle Nerve 73(4) 566-574

PMID41517964
PMCIDPMC12969971
DOI10.1002/mus.70135
发表日期2026-01-10
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIGURE 1:生活质量量表图;FIGURE 2:图注未提示 KM 曲线;FIGURE 3:图注未提示 KM 曲线;FIGURE 4:图注未提示 KM 曲线。
摘要

摘要

INTRODUCTION/AIMS: Sex-specific differences in myasthenia gravis (MG) are widely acknowledged, yet data on sex-based outcomes of MG treatment are scarce. In accordance with Sex and Gender Equity in Research guidelines, this post hoc analysis assessed potential sex-specific differences in treatment outcomes in acetylcholine receptor antibody-positive (AChR-Ab+) generalized (g)MG participants in the Phase 3 ADAPT trial (NCT03669588). METHODS: Participants received four once-weekly efgartigimod infusions (10 mg/kg) or placebo per cycle. Endpoints (primary: proportion of Myasthenia Gravis Activities of Daily Living (MG-ADL) responders (Cycle 1); secondary: proportion of Quantitative Myasthenia Gravis (QMG) and early (Cycle 1) MG-ADL responders, and time with clinically meaningful improvements in MG-ADL score; additional: quality of life outcomes, pharmacodynamics) were assessed according to sex. RESULTS: Females were younger (mean age: 42.9 vs. 54.8 years), more likely to have undergone thymectomy (65.1% [56/86] vs. 44.2% [19/43]), and had higher baseline QMG scores (16.3 vs. 14.3) compared with males. Efgartigimod demonstrated homogeneous effects between sexes, with no significant difference in proportions of MG-ADL (p = 0.7014), early (Cycle 1) MG-ADL (p = 1.00), or QMG responders (p = 0.1595). Improvements in quality-of-life assessments, rates of minimal symptom expression, and mean total immunoglobulin G reductions (Cycle 1) were greater with efgartigimod verso placebo in females and males. Efgartigimod was well tolerated, with similar safety profiles across sexes. DISCUSSION: In ADAPT, efgartigimod-treated female and male AChR-Ab+ gMG patients had similar efficacy and safety outcomes. These data provide valuable insight for clinicians, given the established sex differences in MG disease course and treatment responses. TRIAL REGISTRATION: The ADAPT trial is registered on ClinicalTrials.gov (NCT03669588).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1Mean change in (a) total MG‐ADL score, (b) QMG score, and (c) MG‐QoL15r score during Cycle 1 in the modified intent‐to‐treat population, by sex at birth. Error bars represent SD. EFG, efgartigimod; MG‐ADL, Myasthenia Gravis Activities of Daily Living; MG‐QoL15r, Myasthenia Gravis Quality of Life Questionnaire; PBO, placebo; QMG, Quantitative Myasthenia Gravis; SD, standard deviation.
非 KM Figure
FIGURE 2Minimum point improvement in (a) total MG‐ADL score and (b) QMG score during Cycle 1 (Week 4) in the modified intent‐to‐treat population, by sex at birth. EFG, efgartigimod; MG‐ADL, Myasthenia Gravis Activities of Daily Living; PBO, placebo; QMG, Quantitative Myasthenia Gravis.
非 KM Figure
FIGURE 3Proportion of participants achieving MSE during the first cycle in the modified intent‐to‐treat population, by sex at birth. a MSE describes achieving an MG‐ADL score of 0 or 1 at any post‐baseline visits within the corresponding cycle. EFG, efgartigimod; MG‐ADL, Myasthenia Gravis Activities of Daily Living; MSE, minimal symptom expression; PBO, placebo.
非 KM Figure
FIGURE 4Change in total IgG level during Cycle 1 in the modified intent‐to‐treat population, by sex at birth. Error bars show standard error. EFG, efgartigimod; IgG, immunoglobulin G; PBO, placebo.
非 KM Figure